Open-label, Multicentric Phase I-II Trial to Evaluate the Efficacy and Safety of the Combination of Sorafenib (BAY 43-9006), Gemcitabine and Concurrent Radiotherapy, in Locally Advanced Pancreatic Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 28 Nov 2012
At a glance
- Drugs Gemcitabine (Primary) ; Sorafenib (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Nov 2008 New trial record.